Literature DB >> 18669817

Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis.

Elliott C Dasenbrook1, Christian A Merlo, Marie Diener-West, Noah Lechtzin, Michael P Boyle.   

Abstract

RATIONALE: The prevalence in cystic fibrosis (CF) of respiratory cultures with methicillin-resistant Staphylococcus aureus (MRSA) has dramatically increased over the last 10 years, but the effect of MRSA on FEV(1) decline in CF is unknown.
OBJECTIVES: To determine the association between MRSA respiratory infection and FEV(1) decline in children and adults with CF.
METHODS: This was a 10-year cohort study using the Cystic Fibrosis Foundation patient registry from 1996-2005. We studied individuals who developed new MRSA respiratory tract infection. Repeated-measures regression was used to assess the association between MRSA and FEV(1) decline, adjusted for confounders, in individuals aged 8-21 years and adults (aged 22-45 yr). Two different statistical models were used to assess robustness of results.
MEASUREMENTS AND MAIN RESULTS: The study cohort included 17,357 patients with an average follow-up of 5.3 years. During the study period, 1,732 individuals developed new persistent MRSA infection (> or =3 MRSA cultures; average, 6.8 positive cultures) and were subsequently followed for an average of 3.5 years. Even after adjustment for confounders, rate of FEV(1) decline in individuals aged 8-21 years with persistent MRSA was more rapid in both statistical models. Their average FEV(1) decline of 2.06% predicted/year was 43% more rapid than the 1.44% predicted/year in those without MRSA (difference, -0.62% predicted/yr; 95% confidence interval, -0.70 to -0.54; P < 0.001). Effect of MRSA on FEV(1) decline in adults was not clinically significant.
CONCLUSIONS: Persistent infection with MRSA in individuals with CF between the ages of 8 and 21 years is associated with a more rapid rate of decline in lung function.

Entities:  

Mesh:

Year:  2008        PMID: 18669817     DOI: 10.1164/rccm.200802-327OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  102 in total

1.  Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis.

Authors:  Rebecca A Keel; Andre Schaeftlein; Charlotte Kloft; J Samuel Pope; R Frederic Knauft; Marianne Muhlebach; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

Review 2.  Unmet needs in cystic fibrosis: the next steps in improving outcomes.

Authors:  Natalie E West; Patrick A Flume
Journal:  Expert Rev Respir Med       Date:  2018-06-19       Impact factor: 3.772

3.  Year-to-year changes in lung function in individuals with cystic fibrosis.

Authors:  Theodore G Liou; Eric P Elkin; David J Pasta; Joan R Jacobs; Michael W Konstan; Wayne J Morgan; Jeffrey S Wagener
Journal:  J Cyst Fibros       Date:  2010-05-14       Impact factor: 5.482

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Emergence and Within-Host Genetic Evolution of Methicillin-Resistant Staphylococcus aureus Resistant to Linezolid in a Cystic Fibrosis Patient.

Authors:  Caroline Rouard; Fabien Garnier; Jeremy Leraut; Margaux Lepainteur; Lalaina Rahajamananav; Jeanne Languepin; Marie-Cécile Ploy; Nadège Bourgeois-Nicolaos; Florence Doucet-Populaire
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 6.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

7.  Evaluation of Vancomycin Dosing in Pediatric Cystic Fibrosis Patients.

Authors:  Erin J McDade; Jennifer L Hewlett; Siby P Moonnumakal; Carol J Baker
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr

Review 8.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

9.  Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients.

Authors:  Deanna M Green; Kathryn E McDougal; Scott M Blackman; Patrick R Sosnay; Lindsay B Henderson; Kathleen M Naughton; J Michael Collaco; Garry R Cutting
Journal:  Respir Res       Date:  2010-10-08

10.  Longitudinal survey of Staphylococcus aureus in cystic fibrosis patients using a multiple-locus variable-number of tandem-repeats analysis method.

Authors:  Hoang Vu-Thien; Katia Hormigos; Gaëlle Corbineau; Brigitte Fauroux; Harriet Corvol; Didier Moissenet; Gilles Vergnaud; Christine Pourcel
Journal:  BMC Microbiol       Date:  2010-01-27       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.